Ledipasvir and sofosbuvir for hepatitis C genotype 4: A proof-of-concept, single-centre, open-label phase 2a cohort study

The Lancet Infectious Diseases

Volumn 15, Issue 9, 2015, Pages 1049-1054

  Kohli, Anita ^a,c   Kapoor, Rama ^c   Sims, Zayani ^a   Nelson, Amy ^d   Sidharthan, Sreetha ^a   Lam, Brian ^e   Silk, Rachel ^c   Kotb, Colleen ^c   Gross, Chloe ^c   Teferi, Gebeyehu ^f   Sugarman, Kate ^f   Pang, Phillip S ^g   Osinusi, Anu ^g   Polis, Michael A ^b   Rustgi, Vinod ^h   Masur, Henry ^a   Kottilil, Shyam ^d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e INOVA FAIRFAX HOSPITAL   (United States)

^f Unity Health Care   (United States)

^g GILEAD SCIENCES   (United States)

^h UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA; BENZIMIDAZOLE DERIVATIVE; DRUG COMBINATION; FLUORENE DERIVATIVE; LEDIPASVIR; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS C; CHRONOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; INTENTION TO TREAT ANALYSIS; LIMIT OF QUANTITATION; LIVER CIRRHOSIS; MALE; MONOTHERAPY; NAUSEA; NEUTROPHIL COUNT; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; AGED; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; VIRUS LOAD;

AGED; BENZIMIDAZOLES; DNA, VIRAL; DRUG COMBINATIONS; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; SOFOSBUVIR; VIRAL LOAD;

EID: 84939815619     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00157-7     Document Type: Article

References (23)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57:1333-1342.
2. Alter HJ, Seeff LB Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000, 20:17-35.
3. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014, 61(suppl 1):S45-S57.
4. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2014, 61:77-87.
5. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014, 61(suppl 1):S45-S57.
6. Recommendations for testing, managing, and treating hepatitis C AASLD/IDSA/IAS-USA, (accessed March 3, 2015). http://www.hcvguidelines.org.
7. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014, 370:1483-1493.
8. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014, 370:1889-1898.
9. Kohli A, Shaffer A, Sherman A, Kottilil S Treatment of hepatitis C: a systematic review. JAMA 2014, 312:631-640.
10. Wantuck JM, Ahmed A, Nguyen MH Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 2014, 39:137-147.
11. Table for grading the severity of adult and pediatric adverse events Division of AIDS, (accessed Feb 2, 2015). http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingtable.pdf.
12. Shaheen AA, Wan AF, Myers RP FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007, 102:2589-2600.
13. Halfon P, Bourliere M, Deydier R, et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006, 101:547-555.
14. Ruane PJ AD, Meshrekey R, Riad J, et al. Sofosbuvir plus ribavirin, an interferon-free regimen, in the treatment of treatment naive and treatment experienced patients wtih chronic genotype 4 HCV infection. 49th Annual Meeting of the European Association for the Study of the Liver; London, UK; April 9-13, 2014. Abstract P1243.
15. Molina JM, Orkin C, Iser DM, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotypes 1, 2, 3 and 4 infection in patients co-infected with HIV (PHOTON-2). 20th International AIDS Conference 2014; July 20-25, 2014; Melbourne, Australia. Abstract MOAB0105LB.
16. Hezode C, Asselah T, Reddy R, Hassanein T, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic virus infection (PEARL-1): a randomised, open-label trial. Lancet 2015, 385:2502-2509.
17. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368:1878-1887.
18. Naggie S Management of hepatitis C virus infection: the basics. Top Antivir Med 2012, 20:154-161.
19. Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013, 310:804-811.
20. Harvoni prescribing information Gilead Sciences, (accessed Feb 2, 2015). http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf.
21. Pollack A Harvoni, a hepatitis C drug from Gilead, wins F.D.A. approval. The New York Times (New York) Oct 10, 2014, (accessed Jan 29, 2015). http://www.nytimes.com/2014/10/11/business/harvoni-a-hepatitis-c-drug-from-gilead-wins-fda-approval.html?_r=0.
22. Harris G Maker of costly hepatitis C drug Sovaldi strikes deal on generics for poor countries. The New York Times (New York) Sept 15, 2014, (accessed Jan 29, 2015). http://www.nytimes.com/2014/09/16/business/international/maker-of-hepatitis-c-drug-strikes-deal-on-generics-for-poor-countries.html.
23. Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007, 46:1732-1740.